Supplementary Material
Published: 29 September 2025| Version 1 | DOI: 10.17632/cym53n6676.1
Contributors:
, , , , , , , , , Description
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa
Files
Categories
Immunology, Dermatology, Hidradenitis Suppurativa
Funding
Eli Lilly (United States)